Letters
Dear Sir,
In the era of evidence-based laboratory medicine, the recent review of cryoglobulin laboratory evaluation 1 makes recommendations that, in my view, are inappropriate for many laboratories. The recommendations that 'Detailed characterisation and typing of the cryoprecipitate should always be performed', and that quantitation of the cryoglobulin needs to be done on all specimens, need to be backed up by evidence that these procedures will actually alter patient management and benefit patients.
Typing and quantitation are labour-intensive, and involve extensive manual handling of specimens that are often highly infectious. In our laboratory the vast majority of cryoglobulins are found in patients who are known to have hepatitis C; the clinical question being asked is simply 'does this patient have a cryoglobulin which can explain their symptoms?' and typing or quantitation of the cryoglobulin adds nothing to their management. We have a simpler protocol: after three days at 48C, the presence/absence of a cryoglobulin is reported, a protein electrophoresis is done on the 378C sample, and detailed further analyses are performed only if requested by the clinicians. This has proved perfectly satisfactory, and we get very few requests for typing or quantitation.
In addition, the recommendation that precipitation needs to be continued for seven days is not backed up by any evidence. It has always seemed highly unlikely that a cryoglobulin which only precipitates after more than three days at 48C would have any chance of precipitating in vivo. I suspect that such lateprecipitating cryoglobulins are an incidental finding and do not relate to clinical effects in the patient, and I have never seen any evidence to contradict this common-sense view.
Laboratory practice in the real world is constrained by resource limitations, and good laboratory practice entails optimizing resource allocation, and not always performing all possible tests that may be appropriate in a reference laboratory.
Appropriate cryoglobulin investigations -the author responds
Dear Sir, Davidson 1 raises some interesting and valid points for discussion in response to our review article. 2 Characterization and typing of the cryoprecipitate should always be performed as the type of the cryoglobulin is strongly indicative of the most likely aetiology. In a type 1 cryoglobulin, one would look hard for a lymphoproliferative disease whereas a type 2 or type 3 cryoglobulin would be investigated differently. A cryoglobulin in the context of Sjogren's is very different from the one in hepatitis infection.
Is known hepatitis C virus (HCV) status a barrier to proper characterization? A laboratory that follows good practice in sample handling should be able to deal with category 3 samples and it should not be a deterrent to proper processing, characterization and typing of a cryoprecipitate. A significant number of unknown infectious samples are handled by any large laboratory every day, hence universal sample handling precautions. Knowledge of the potential risk status of an individual serum allows risk assessment, and in our laboratory we do not shy away from characterization on the basis of known HCV infection, but only where clinically relevant.
Davidson 1 states that the vast majority of cryoglobulin requests in their laboratory are from patients who are known to have HCV infection with a 'simple question' -'does this patient have a cryoglobulin which can explain their symptoms?' The assumption is that many patients with HCV infection require this test on clinical grounds. Previous studies by one of us would suggest that .90% of infected patients do not, and those who have clinical symptoms have other clues to aetiopathogenesis, such as larger cryoglobulins and monoclonal componentsmaking typing and some form of locally validated quantitation quite important, at least in the UK population studied. 3 Mixed cryoglobulins are reported in 20-56% of HCV-infected individuals, 4,5 but only 5 -27% of the HCV cryoglobulins cause cryoglobulinaemic syndromes and there are usually other clues pointing to this pathology. 6 Complement levels vary in cryoglobulinaemia and are insufficient when used alone. As we clearly recommend in our review, cryoglobulin testing should be reserved for patients with appropriate clinical symptoms and should not be offered if there are no symptoms attributable to cryoglobulinaemia.
Good laboratory practice includes liaison with users to determine whether the testing strategy is appropriate; educating laboratory users where it is not; appropriate requesting and gating of tests; and once a test is done, proper interpretation.
In response to the valid questions raised by Davidson, 1 we would ask, what are the criteria used by the clinicians
